Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Linaclotide | Plecanatide |
|---|---|---|
| Class | Guanylate cyclase-C agonist | Guanylate cyclase-C agonist |
| Research category | chronic constipation and IBS-C | chronic constipation and IBS-C |
| Evidence level | High | High |
| Overall status | Approved (Rx) — chronic constipation and IBS-C | Approved (Rx, US) — chronic constipation and IBS-C |
| FDA | Approved (Rx) | Approved (Rx) |
| EMA | Approved (Rx) | Not approved |
| WADA | Not listed | Not listed |
| Mechanism studied | Linaclotide → GC-C receptor → cGMP & CFTR → Intestinal secretion ↑ | Plecanatide → GC-C receptor (pH-dependent) → cGMP signalling → Intestinal transit |
| Molecular weight | 1,526.8 g/mol | 1,681.9 g/mol |
| Sizes in stock | Not currently listed | Not currently listed |
Where the research overlaps
Both compounds are studied within Metabolic & GLP-1 research. Linaclotide is classed as guanylate cyclase-c agonist, while Plecanatide is guanylate cyclase-c agonist. Evidence is rated high for Linaclotide and high for Plecanatide.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.